IMO in an under powered study you need to do this kind of speculative analyses to get new thoughts to get forward and it is very obvious that Prana has been doing similar type of analyses (as was Masters). To me the Imagine study was unfortunately only a pilot study.
Interestingtome has only less information than Prana has and he has no access to the info possibly explaining these odd cases he is eliminating. When I was looking the hippocampus vol slide of Masters, I did also eliminate in my mind the placebo case increasing hippocampus vol to srink the standard error of mean. Unfortunately we had also in the PBT2 group a similar "Mr. Lawler" case, but because the number of cases was bigger the effect of one odd case on standard error of mean was not so big as in the placebo group.
15 cases in the placebo group was clearly too small number but IMO it is useful to do what interestingtome did to see the possible background trends. When you can see a statistical trend in this kind of small material it is a very strong signal that the drug works. It is much more difficult to demonstrate that a drug does not work. In the 2care study it took some 3000 patient years and 1500 in the placebo group. Now with 15 patient years in the placebo group we have a strong trend. There will be never a study telling that PBT2 does not work and interestingtome's analyses are helpful to us to see this in spite the definitive proof will come only later.
Amazing isn't it ... your writing on a stock board that you despise... I guess your not enjoying the ride up on the trading last few days.. go back to shorting 101 school and learn a few things
Sentiment: Strong Buy
What is actually amazing to me is that there are people who post on these boards without adding or bringing any substance or conversation.
It"s actually amazing that some people do not value their own time and energy. Why are you here?
for some reason its not letting me post the rest of the abstract :( on HC anyway
Introduction: Huntington's disease is a hereditary neurodegenerative disease. It is designated as a rare disease in the US, which means there are less than 200,000 patients in the country who suffer from it. The drugs that are currently used to treat this disease were not designed specifically for it but developed for other diseases. Presently, two classes of drugs are being developed; those that provide symptomatic relief and those that may modify course of the disease. Areas covered: This review is focused on seven selected drugs currently in clinical testing and describes their progress. Five of the seven drugs that are reviewed here, can be categorized as 'symptomatic' drugs, and, selisistat and PBT-2 are amongst the ones that would qualify as 'disease modifying' drugs. Expert opinion: The authors believe that the future treatment paradigm for this disease is best met by using a disease-modifying drug that can be administered together with symptomatic drugs. Towards that end, it is important for the industry to focus on disease-modifying drugs by targeting unique pathways and targets. Furthermore, they propose that neuroprotective drugs, that is, drugs that directly work by preserving neuronal health and function is an opportunity for such disease-modifying drugs.
Expert Opin Investig Drugs. 2014 Aug 1:1-9. [Epub ahead of print]
Investigational drugs for the management of Huntington's disease: are we there yet?
Kulkarni P1, Saxena U.
Introduction: Huntington's disease is a hereditary neurodegenerative disease. It is designated as a rare disease in the US, which means there are
Sentiment: Strong Buy
I am as optimistic as most of us. However, this article is one of the auto-generated pieces of "news". Create a template, fill in the blanks and post it online.
How investors can get devastated by a stock and then come back for more. What they need is a good shot with a 2x4 to knock some sense into them instead! The current pumpers on the board benefited from their pumping previously and are trying to do it again. If you want to listen to all the BS, then you deserve what is likely to happen. The pumpers bail and the investors get burned! You've been cautioned as I hate to see people lose their hard earned money. Its your money and your choice. GL.
Yes been saying the same thing for a few weeks. Doubt it will break the 2.80 till 200 day average gets lower in Nov. Still a pop could be in the cards in Sept. Note the street said NOTHING that the company its self was a good buy but a trading stock ( what I have been saying). A trader can pickup 20-25% pops every so often. But you need to SELL to make this trade work.